CASE REPORT
Published on 20 Dec 2024
Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation
doi 10.3389/fonc.2024.1468532